Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
02/02/2023 - 04:05 PM
– Presentations to be webcast on www.exelixis.com –
ALAMEDA, Calif. --(BUSINESS WIRE)--
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February:
Guggenheim Healthcare Talks Oncology Day 2023: Exelixis is scheduled to present at 11:20 am ET / 8:20 am PT on Thursday, February 9 in New York .
SVB Securities Global Biopharma Conference : Exelixis is scheduled to present virtually at 2:20 pm ET / 11:20 am PT on Wednesday, February 15 .
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for at least 30 days.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on Twitter, like Exelixis, Inc. Exelixis
Exelixis , the Exelixis logo and CABOMETYX are registered U.S. trademarks.
View source version on businesswire.com : https://www.businesswire.com/news/home/20230202005807/en/
Investors Contact:
Varant Shirvanian
Associate Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
Source: Exelixis, Inc.
EXEL Rankings
#860 Ranked by Stock Gains
EXEL Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
About EXEL
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
